D. Boral Capital Reiterates 'Buy' Rating for FibroBiologics

Analysts maintain positive outlook on biotech firm's stock despite recent price target reduction

Mar. 12, 2026 at 9:06pm

Got story updates? Submit your updates here. ›

Equity research firm D. Boral Capital has reaffirmed its 'buy' rating for shares of FibroBiologics (NASDAQ:FBLG), a Houston-based cell therapy and regenerative medicine company. This comes despite another analyst, HC Wainwright, lowering its price target for FibroBiologics' stock to $4.00 from a previous target.

Why it matters

FibroBiologics is developing a pipeline of treatments for chronic diseases using its proprietary fibroblast cell technology. Maintaining a 'buy' rating from a major research firm despite a price target reduction suggests analysts see long-term potential in the company's innovative approach, even as near-term challenges may impact the stock price.

The details

D. Boral Capital's analysts have kept their $7.00 price target on FibroBiologics' stock, while HC Wainwright lowered its target to $4.00. The company reported a narrower-than-expected loss in its most recent quarterly earnings. FibroBiologics holds over 150 patents and patents pending globally for its fibroblast-based therapies targeting conditions like disc degeneration, multiple sclerosis, and cancer.

  • FibroBiologics last reported quarterly earnings on February 24, 2026.
  • D. Boral Capital issued its 'buy' rating and $7.00 price target on March 12, 2026.
  • HC Wainwright reduced its price target to $4.00 on February 26, 2026.

The players

D. Boral Capital

An equity research firm that has maintained a 'buy' rating on FibroBiologics' stock.

FibroBiologics

A Houston-based cell therapy and regenerative medicine company developing treatments for chronic diseases using its proprietary fibroblast cell technology.

HC Wainwright

Another equity research firm that has lowered its price target for FibroBiologics' stock.

Got photos? Submit your photos here. ›

The takeaway

Despite a price target reduction from one research firm, FibroBiologics maintains a 'buy' rating from a major analyst, suggesting the company's innovative fibroblast-based therapies still have long-term potential even as near-term challenges impact the stock price.